

1 **Title Page**

2
3 **Title: METTL7A improves bovine IVF embryo competence by attenuating oxidative stress**

4
5 **Running title: METTL7A improves embryo competence**

6
7
8 Linkai Zhu¹, Hao Ming¹, Giovanna N. Scatolin¹, Andrew Xiao², Zongliang Jiang^{1,#}

9
10 ¹ Department of Animal Sciences, Genetics Institute, University of Florida, Gainesville, FL, USA

11 ² Department of Genetics, School of Medicine, Yale University, New Haven, CT, USA

12
13 # To whom correspondence will be addressed: z.jiang1@ufl.edu.

14
15 **Abstract**

16
17 In vitro fertilization (IVF) is a widely used assisted reproductive technology to achieve a
18 successful pregnancy. However, the acquisition of oxidative stress in embryo in vitro culture
19 impairs its competence. Here, we demonstrated that a nuclear coding gene, methyltransferase-
20 like protein 7A (METTL7A), improves the developmental potential of bovine embryos. We found
21 that exogenous METTL7A modulates expression of genes involved in embryonic cell
22 mitochondrial pathways and promotes trophectoderm development. Surprisingly, we discovered
23 that METTL7A alleviates mitochondrial stress and DNA damage and promotes cell cycle
24 progression during embryo cleavage. In summary, we have identified a novel mitochondria
25 stress eliminating mechanism regulated by METTL7A that occurs during the acquisition of
26 oxidative stress in embryo in vitro culture. This discovery lays the groundwork for the
27 development of METTL7A as a promising therapeutic target for IVF embryo competence.

28
29 **Keywords:** METTL7A, IVF, embryo competence, oxidative stress, mitochondria, DNA damage

30
31 **Summary statement (Graphic abstract):** We describe a molecule acts in the pre-implantation
32 period to attenuate oxidative stress that enhances embryo development to the blastocyst stage
33 and subsequent pregnancy in cattle.

35 Introduction

36

37 Embryo in vitro production (IVP) technology has been widely used to treat human infertility and
38 improve the reproduction efficiency of agricultural species, such as cattle. The number of IVP
39 embryos transferred has steadily increased over the years globally both from humans [1] and
40 domestic species [2]. However, the competence of IVP embryos to establish pregnancy is much
41 lower than the embryos produced in vivo. It is believed these complications associated with IVF
42 embryos are induced by the environmental stressors accumulated during in vitro embryo culture
43 [3, 4].

44

45 Gametes and embryos are exposed to high levels of oxidative stress in in vitro culture
46 conditions [5, 6]. Oxygen (O₂) tension is one of the major sources that lead to oxidative stress
47 [7]. The atmospheric concentration of O₂ (20%) used in the embryo culture system is
48 considerably greater than the oxygen tension in the oviduct and uterus of mammals [8]. Studies
49 across multiple species have shown improved in vitro embryo development when oxygen levels
50 are reduced from 20% to 5% [9]. This elevated O₂ level during embryonic development can
51 influence gene expression, metabolism, and the activity of important epigenetic enzymes.
52 Another major contributor of oxidative stress is reactive oxygen species (ROS), which are by-
53 products of oxidative phosphorylation within the mitochondria [10]. Under physiological
54 conditions, ROS level is closely monitored and controlled by antioxidants [11]. However,
55 mitochondrial dysfunction and impaired antioxidant defense system can lead to the generation
56 of excess ROS, resulting in delayed development, DNA damage, apoptosis or lipid peroxidation
57 [12].

58

59 To mitigate the detrimental effect of oxidative stress on IVP embryo culture to promote embryo
60 competence, multiple approaches have been explored in addition to the reduced oxygen tension,
61 including co-culture with cumulus cells as ROS scavenger [13, 14], supplement of exogenous
62 antioxidants to reduce ROS such as anethole [15], beta-mercaptoethanol [16, 17], imperatorin
63 [18], N-(2-mercaptopropionyl)-glycine [19], and dihydromyricetin [20]. Boosting the endogenous
64 antioxidants such as reduced GSH has also been tested [21]. GSH is the main non-protein
65 sulfhydryl compound in mammalian cells with ability to protect cells from oxidative stress [22].
66 The synthesis of GSH is dependent on the availability of cysteine, of which intracellular cysteine
67 can be acquired from methionine metabolism [23]. During this process, methionine is first
68 metabolized into S-adenosyl-L-methionine (SAM), which can donate its methyl group to a wide

69 range of molecules catalyzed by methyltransferases and yield S-adenosyl-homocysteine (SAH).
70 SAH undergoes a series of hydrolysis reactions to release free cysteine for GSH synthesis [23].

71
72 Recently, a nuclear coding gene, methyltransferase-like protein 7A (*METTL7A*), has been
73 characterized as an endoplasmic reticulum (ER) transmembrane protein involving in lipid droplet
74 formation [24, 25], and it possesses SAM-dependent thiol methyltransferase activity, also
75 named as *TMT1A* [26], thus, it may potentially regulate GSH synthesis. So far, limited studies
76 have shown *METTL7A* is associated with the successful stem cell reprogramming trajectory [27],
77 and can promote cell survival and modulate metabolic activities [28]. However, the biological
78 function of *METTL7A* is largely unknown and the specific role of *METTL7A* during early
79 embryonic development remains unexplored. The aim of this study has been to test the
80 hypothesis that *METTL7A* alleviates oxidative stress and improves the embryo competence
81 using bovine IVF embryos.

82
83
84

85 **Materials and Methods**

86

87 **Animal care and use**

88

89 Bovine peri-implantation embryos were collected from non-lactating, 3-year-old crossbreed (*Bos*
90 *taurus* x *Bos indicus*) cows. The animal experiments were conducted under animal use
91 protocols (202300000191) approved by the Institutional Animal Care and Use Committee of the
92 University of Florida. All cows were housed in open pasture, and under constant care of the
93 farm staff.

94

95 **Bovine oocytes and in vitro embryo production**

96

97 Germinal vesicle stage oocytes (GV oocytes) were collected as cumulus-oocyte complexes
98 (COCs) aspirated from slaughterhouse ovaries. In vitro maturation was conducted using BO-
99 IVM medium (IVF Bioscience, Falmouth, UK) for 22-23 hours at 38.5°C with 6% CO₂ to collect
100 MII oocytes. Cryopreserved semen from a Holstein bull with proven fertility was prepared with
101 BO-SemenPrep medium (IVF Bioscience, Falmouth, UK) and added to drops containing COCs
102 with a final concentration of 2 x 10⁶ spermatozoa/ml for in vitro fertilization. Gametes were co-

103 incubated under 38.5 °C and 6% CO₂. After 10 hours (microinjected embryo experiments) or 16
104 hours (non-microinjected embryo experiments) in BO-IVF medium (IVF Biosciences, Falmouth,
105 UK), IVF embryos were denuded from cumulus cells by vortexing for 5 min in BO-Wash medium
106 (IVF Bioscience, Falmouth, UK) and cultured up to 7.5 d in BO-IVC medium (IVF Biosciences,
107 Falmouth, UK) at 38.5 °C, 6% CO₂, and 6% O₂. Different developmental stage embryos were
108 then evaluated under light microscopy following embryo grade standards of the International
109 Embryo Technology Society. Cleavage rate and blastocyst rate, defined as percentage of
110 cleavage embryos and blastocysts over presumptive zygotes, were measured at embryonic day
111 3.5 (E3.5) and 7.5 (E7.5), respectively.

112
113

114 **In vitro transcription of *METTL7A***

115

116 Total RNA was extracted from a pool of 50 bovine IVF embryos (E7.5), embryonic stem cells,
117 and trophoblast stem cells [29, 30], followed by first strand cDNA synthesis using SuperScript™
118 IV VILO™ Master Mix (Thermo Fisher Scientific, Waltham, MA). Primers were designed based
119 on the current genome annotation (ARS-UCD2.0; National Center for Biotechnology Information)
120 to include 5'- and 3'- UTR regions of *METTL7A* (Table S1). PCR was conducted using Q5 Hot
121 Start High-Fidelity 2X Master Mix (New England Biolabs, Ipswich, MA) with an initial
122 denaturation step at 98°C for 30 seconds followed by 30 cycles at 98°C for 10 seconds,
123 annealing at 58°C for 30 seconds and extension at 72 °C for 30 seconds and a final extension
124 at 72 °C for 2 minutes. The purified PCR products were served as DNA template for in vitro
125 transcription using HiScribe® T7 ARCA mRNA Kit (New England Biolabs, Ipswich, MA) with
126 tailing following manufacture's instruction. The yield and integrity of resulting mRNA were
127 assessed using Qubit 4 (Thermo Fisher Scientific, Waltham, MA) and Tapestation 4150 (Agilent
128 Technologies, Santa Clara, CA).

129

130 To generate *METTL7A-6xHis* mRNA, two pairs of primers (Table S1) were designed to produce
131 PCR fragments with an overlapping region which contains 6xHis sequence before the stop
132 codon of *METTL7A*. The two fragments were then assembled using NEBuilder® HiFi DNA
133 Assembly Master Mix (New England Biolabs, Ipswich, MA), followed by in vitro transcription
134 using using HiScribe® T7 ARCA mRNA Kit (New England Biolabs, Ipswich, MA). To
135 overexpress *METTL7A*, in vitro transcribed mRNAs (IVT-mRNAs) were microinjected into
136 presumptive zygotes or one blastomere of the 2-cell embryo at final concentration of 10 ng/ul.

137 Approximately 1 μ l of solution was injected. In each replicate, approximately 30 presumptive
138 zygotes were injected in one section and cultured together in 50 μ l BO-IVC medium. Embryo
139 development rates were recorded from different batches/days of experiments. Data points were
140 excluded only when blastocyst rate from IVF control dropped below 30%, particularly during hot
141 seasons when heat stress may affect oocyte quality [31]. Nuclease-free Tris-EDTA buffer
142 (TEKNOVA T0223, Hollister, CA), which was used to resuspend IVT-mRNAs, was injected in
143 the vehicle control group.

144 .

145

146 **Immunofluorescence and Data Analysis**

147

148 Bovine embryos and embryonic cells from different batches/days of experiments were fixed in
149 freshly made 4% paraformaldehyde (Electron Microscopy Science, Hatfield, PA) at room
150 temperature for 15 minutes followed by permeabilization in 1% (v/v) Triton X-100 (Sigma,
151 Burlington, MA) for 20 minutes and blocking at room temperature for 1 hour in 0.1% (v/v) Triton
152 X-100, 0.1M glycine, 2.5% (w/v) BSA (Sigma, Burlington, MA) and 2.5% (v/v) corresponding
153 serum from the host where the secondary antibodies were derived. Samples were then
154 incubated with primary antibodies (Table S1) at 4°C overnight. After three washes in 0.1% (v/v)
155 Triton X-100 and 0.1% (w/v) polyvinylpyrrolidone (PVP; Sigma, Burlington, MA) in Dulbecco's
156 phosphate buffered saline (DPBS; Thermo Fisher Scientific, Waltham, MA), secondary
157 antibodies (Table S1) were added and incubated at room temperature for 1 hour followed by
158 three washes and mounting on the slide. Confocal images were taken with Olympus IX81-DSU
159 (Cytometry Core Facility, University of Florida, RRID:SCR 019119) and analyzed with ImageJ
160 (V1.53, National Institutes of Health).

161

162 **Embryo Transfer**

163

164 After zygotic injection, ten E6 morulae were transferred to each recipient cows (n = 2) following
165 synchronization with initial intramuscular injection of gonadotropin-releasing hormone (Fertagyl;
166 Merck, Rahway, NJ), standard 7-day vaginal controlled internal drug release (EAZI-BREED
167 CIDR; Zoetis, Parsippany-Troy Hills, NJ) of progesterone, one dose of prostaglandin (Lutalyse;
168 Zoetis, Parsippany-Troy Hills, NJ) upon CIDR removal and another dose of gonadotropin-
169 releasing hormone 48 hours after CIDR removal. Heat detection was determined by scratch of
170 ESTROTECT patches (ABS GLOBAL, DeForest, WI). A cohort of ten morulae from control or

171 treatment group were loaded into 0.5 ml straws in prewarmed Holding Medium (ABT 360,
172 Pullman, WA) and transferred non-surgically to the uterine horn ipsilateral to corpus luteum as
173 detected by transrectal ultrasound. Embryos were recovered by standard non-surgical flushing
174 with lactated ringer's solution (ICU Medical, San Clemente, CA) supplemented with 1% (v/v)
175 fetal bovine serum on embryonic day 12. After flushing, all surrogate cows were given one dose
176 of 5 ml prostaglandin.

177

178 **Interferon-Tau Assay**

179

180 Blood samples from recipients were collected from the coccygeal vein using serum separator
181 tubes on the day of flushing, and immediately stored in refrigerator before centrifugation for 15
182 minutes at 1000 x g. Serum interferon tau (IFN τ) level was measured with Bovine Interferon-Tau
183 ELISA Kit (CUSABIO, Houston, TX) per manufacture's instruction. Briefly, 100 μ l standard or
184 sample were added to each well of 96-well plate provided in the kit and incubated for 2 hours at
185 37 °C. Liquid was withdrew and 100 μ l biotin-antibody was added to each well, followed by 1
186 hour incubation at 37 °C. The solution was discarded, and the wells were washed three times
187 with 200 μ l Wash Buffer. To remove any remaining Wash Buffer in the wells, the plate was
188 inverted and placed on clean paper towel for 1 minute. 100 μ l HRP-avidin was then added to
189 each well and incubated for 1 hour at 37 °C followed by five times of washes. For signal
190 detection, 90 μ l TMB Substrate was added and incubated for 20 minutes at 37 °C avoiding light.
191 After incubation, 50 μ l Stop Solution was added to each well while gently shaking the plate to
192 ensure thorough mixing. The plate was measured using a colorimetric microplate reader set to
193 450 nm.

194

195 **Separation of TE and ICM**

196

197 To profile the differential transcriptome during first lineage specification, blastocysts with zona
198 pellucida at embryonic day 7.5 were used for TE/ICM dissociation following a previously
199 published protocol (26). Briefly, 0.25% trypsin (Thermo Fisher Scientific, Waltham, MA) was
200 continuously injected into the blastocysts until a small mass of cells was slowly washed out from
201 the zona pellucida. The cell masses were washed three times with 0.1% PVP and immediately
202 transferred to -80°C until further use or fixed in freshly made 4% paraformaldehyde followed by
203 staining.

204

205 **RNA sequencing analysis**

206

207 Five 2- or 8-cell embryos were pooled in each replicate and TE and ICM cell clumps from 5
208 blastocysts were pooled after separation for RNA-seq library preparation. Embryos and cells
209 were used directly for library preparation without RNA extraction following manufacturers'
210 instructions. Briefly, SMART-Seq v4 Ultra Low Input RNA kit (Takara, Mountain View, CA) was
211 used for cDNA synthesis and amplification. Library preparation was conducted using Nextera
212 XT DNA Library Prep Kit (Illumina, San Diego, CA). The libraries were subject to size selection
213 with 0.6x AMPure XP bead wash (Beckman Coulter, Indianapolis, IN). The concentration of
214 RNA-seq libraries was determined with a Qubit high sensitivity dsDNA HS assay kit (Thermo
215 Fisher Scientific, Waltham, MA). Pooled indexed libraries were then sequenced on the Illumina
216 NovaSeq 6000 platform with 150-bp paired-end reads.

217

218 Multiplexed sequencing reads that passed filters were trimmed to remove low-quality reads and
219 adaptors by Trim Galore (version 0.6.7). The quality of reads after filtering was assessed by
220 FastQC, followed by alignment to the bovine reference genome by HISAT2 (version 2.2.1) with
221 default parameters. The output SAM files were converted to BAM files and sorted using
222 SAMtools6 (version 1.14). Read counts of all samples were quantified using featureCounts
223 (version 2.0.1) with the bovine genome as a reference and were adjusted to provide counts per
224 million (CPM) mapped reads. Pearson correlation and Principal Component analysis were
225 performed with R (Version 4.4.1). Differentially expressed genes were identified using edgeR
226 (version 4.2.1) in R. Genes were considered differentially expressed when they provided a false
227 discovery rate (FDR) of <0.05 and $|\log_2FC| > 1$. Bioconductor package ClusterProfiler (version
228 4.12.1) was used to reveal the Gene Ontology (GO) and KEGG pathways in R.

229

230 **Western Blot and Data Analysis**

231

232 Ten E7.5 blastocysts were washed three times in 0.1% (w/v) PVP and pooled with
233 approximately 5 μ l medium carryover in each replicate. Samples were first heated with 5 μ l
234 2xSDS gel-loading buffer at 95 °C for 5 minutes followed by a quick spin down, and then loaded
235 onto 10% Tris-Glycine Mini Protein Gels (Thermo Fisher Scientific, Waltham, MA). Western blot
236 electrophoresis was conducted at 100 volts for 2 hours. Proteins were transferred from gel to
237 PVDF membrane with an iBlot 3 Western Blot Transfer Device (Thermo Fisher Scientific,
238 Waltham, MA). After transfer, the membrane was washed with 25 ml Tris buffered saline (TBS)

239 for 5 minutes at room temperature followed by blocking with 2.5% (w/v) BSA and 2.5% (v/v)
240 corresponding serum, from the host where the secondary antibodies were derived, for 1 hour at
241 room temperature. The membrane was washed three times for 5 minutes each with 15 ml of
242 TBST (0.1% Tween-20 in TBS). Primary antibodies were added in 10 ml dilution buffer (5% w/v
243 BSA in TBST) and incubated with membrane with gentle agitation overnight at 4°C followed by
244 three times of washes with TBST. Secondary antibodies were added in 10 ml of blocking buffer
245 and incubated with membrane with gentle agitation for 1 hour at room temperature. Membrane
246 was washed three times before proceeded with signal detection. Pierce™ ECL Western Blotting
247 Substrate (Thermo Fisher Scientific, Waltham, MA) was added to the membrane and incubated
248 for 1 minute. Excessive solution was removed before imaging using iBright CL1500 System
249 (Thermo Fisher Scientific, Waltham, MA).

250

251 **Superoxide Assay**

252

253 MitoSOX Green (MSG, Thermo Fisher Scientific, Waltham, MA) reagent stock was prepared by
254 dissolving the contents of the vial in 10 µl of anhydrous DMF, which is stable for one day. To
255 make a working solution, 10 µl of 1mM stock solution was added to HEPES-TALP. 200 µl of
256 working solution was added to one well of µ-Slide (Ibidi, Fitchburg, WI). Live embryos were
257 taken out from culture and washed quickly with HEPES-TALP followed by incubation in MSG
258 working solution for 30 minutes at 38.5 °C, 6% CO₂. After incubation, embryos were washed
259 three times with warm buffer and confocal images were taken within 2 hours of staining.
260 Fluorescence intensity was analyzed with ImageJ and Prism 9 (GraphPad, La Jolla, CA). A two-
261 tailed student's t-test was used for statistical analysis.

262

263 **GSH Assay**

264

265 To measure the level of glutathione in reduced form (GSH), ten 8-cell embryos or five E7.5
266 blastocysts were pooled in each replicate after washing briefly in 0.1% (w/v) PVP/PBS. The
267 level of reduced GSH was quantified indirectly by subtracting oxidized GSH (GSSG) from total
268 GSH using commercial kit GSH/GSSG-Glo™ Assay (Promega, Madison, WI) following
269 manufacturer's instructions. Relative luminescence over no cell control was analyzed with two-
270 tailed student's t-test in Prism 9.

271

272 **Results**

273

274 **Exogenous METTL7A improves the developmental potential of bovine IVP embryos**

275

276 By mining of genome-wide transcriptional and translational datasets [32], we found that
277 METTL7A is barely expressed and translated across bovine oocytes and pre-implantation
278 embryos derived in vitro (Figure S1), suggesting that METTL7A is dispensable for bovine pre-
279 implantation development. To test the biological function of METTL7A during embryogenesis,
280 we microinjected exogenous METTL7A mRNA into zygotes (Table S1) and evaluated the effect
281 of overexpression (OE) of METTL7A during bovine pre-implantation development. While there is
282 no difference in cleavage rate between METTL7A^{OE} and the control group (79.29% vs. 81.42%;
283 N= 980, n =29 for the treatment group; $p = 0.4503$), a 14.32% increase in blastocyst formation
284 rate was observed in METTL7A^{OE} compared to controls (54.96% vs. 40.64%; N= 335, n =11 for
285 the treatment group; $p = 0.0102$) (Figure 1A, B), indicating a beneficial role of METTL7A for
286 bovine pre-implantation development. Additionally, METTL7A^{OE} blastocysts had a normal
287 differentiation into inner cell mass (ICM) and trophectoderm (TE), as assessed by
288 immunostaining analysis of SOX2 and CDX2 (Figure 1C, D), respectively. Notably, the number
289 of TE cells was significant higher in the METTL7A^{OE} blastocysts compared to the control group
290 (134 vs. 87; n = 5; $p = 0.0198$), while ICM cell number was not different (29 vs. 27.6; n = 5; $p =$
291 0.5548), resulting in higher TE/ICM ratio in METTL7A^{OE} blastocysts compared to control (4.81
292 vs. 3.16, $p = 0.0699$) (Figure 1E-G).

293

294 To further determine the viability of METTL7A^{OE} embryos and if they can establish successful
295 pregnancy, we transferred either METTL7A^{OE} or IVF embryos at morula stage to recipient cows
296 and flushed them out on embryonic day 12 (E12) for analysis. We found METTL7A^{OE} embryos
297 displayed normal morphology and lineage differentiation similar to the control group (Figure 1H,
298 J), and initiated maternal recognition of pregnancy as indicated by a comparable serum INF-tau
299 level in the surrogate mothers as IVF embryo transfers (n = 2, Figure 1I).

300

301 These results demonstrated that METTL7A promotes the developmental potential of bovine pre-
302 implantation embryos by facilitating TE lineage development, and that bovine METTL7A^{OE}
303 embryos produce normal pregnancy through conceptus elongation following embryo transfer to
304 recipients. Overall, these results highlight that METTL7A molecule constitutes a promising
305 pharmaceutical target for improving IVF embryo competence.

306

307 **Exogenous METTL7A modulates expression of genes involved in mitochondrial**
308 **functions during bovine pre-implantation development.**

309

310 To understand METTL7A function on gene expression of embryos and embryonic (ICM and TE)
311 lineages, we performed RNA sequencing (RNA-seq) analysis on METTL7A^{OE} and control
312 embryos at 2-, 8-cell and blastocyst stage. ICM and TE were separated by micromanipulation
313 procedures, which were confirmed by immunostaining analysis of lineage markers SOX2 and
314 CDX2, respectively (Figure S2A, B). Pearson correlation and principal component analysis of
315 transcriptomic data indicated consistent values between biological replicates across
316 developmental stage (Figure 2A, B). While the transcriptomes of both METTL7A^{OE} and control
317 embryos were distinct across developmental stages, they appeared to cluster together within
318 the same stage with more notable differences in 2 and 8-cell embryos than blastocysts (ICM
319 and TE) (Figure 2A, B).

320

321 In 2-cell embryos, we found 139 and 632 genes to be up- and down-regulated (FDR P value <
322 0.05, $|\log_2FC| > 1$) in METTL7A^{OE} compared to control embryos, respectively (Figure 2C). The
323 most up-regulated genes include *METTL7A*, *LOC781439*, *BTG2*, *STC1*, *ZSCAN5B*, and
324 *PLA2G7* (Figure 2C, Table S2). Of note, *METTL7A* and *LOC781439* (a pseudogene with
325 truncated sequence of *METTL7A*) were the most regulated genes *with* $\log_2FC > 11$ (Table S2),
326 confirming the overexpression of METTL7A.

327

328 At the 8-cell stage, 112 and 1,436 genes were up- and down-regulated in METTL7A^{OE}
329 compared to control embryos, respectively (Figure 2D, Table S3). Similarly, *METT7A* and
330 *LOC781439* remained the top two up-regulated genes with $\log_2FC > 11$ (Table S3), indicating
331 *METTL7A* overexpression pertains to the 8-cell stage. Other top up-regulated genes included
332 *KRT23*, *TARP*, *CXCL5*, and *SLC4A10* (Table S3), with known biological roles in promoting
333 proliferation [33], DNA damage response [34], tumor progression [35], and pH balance [36],
334 respectively. Compared to 2-cell stage, there were significant more down-regulated genes in
335 METTL7A^{OE} embryos at the 8-cell stage. Only one gene had $\log_2FC < -5$ at the 2-cell stage
336 while 401 genes showed $\log_2FC < -5$ at the 8-cell stage (Figure 2C, D, Table S2, S3). Most of
337 the top down-regulated genes in 8-cell embryos (Table S3) were associated with various stress
338 responses, such as *MAP1LC3C* (as known as *LC3C*) and *OAS1X* that are responsible for
339 antibacterial and antiviral response [37, 38].

340

341 At the blastocyst stage, we observed a larger number of genes differentially expressed in TE
342 than ICM (up-regulated: 1,260 vs. 581; down-regulated: 539 vs. 239) associated with METTL7A
343 overexpression (Figure 2E, F; Table S4, S5). However, METTL7A was no longer up-regulated
344 in the blastocysts (both TE and ICM) (Table S4, S5), indicating that the observed transcriptomic
345 changes were not directly caused by overexpression of *METTL7A* but rather from an altered
346 gene expression cascade induced from cleavage stages.

347
348 Gene ontology (GO) analysis indicated overexpression of METTL7A suppressed genes involved
349 in mitochondrial stress and functions among 8-cell and blastocyst (ICM and TE) stage embryos
350 (Figure 2G-I). On the contrary, the up-regulated genes by overexpression of METTL7A were
351 involved in blastocyst formation at 8-cell stage, tissue development in ICM cells, and voltage-
352 gated potassium and cation channel activities in TE cells, respectively (Figure 2G-I). Given that
353 stress responses demand high energy consumption provided by mitochondria [39], the RNA-
354 seq results suggested that overexpression of METTL7A shifts the paradigm of energy
355 expenditure to favor bovine embryonic development.

356
357 Additionally, genes were found to be precisely modulated in the presence of METTL7A by
358 comparing datasets between stages. For example, there is an earlier activation and up-
359 regulation of HAND1 observed at the 2-cell and the 8-cell embryos (Table S2, S3). HAND1 is
360 essential for trophoblast lineage differentiation and development [40]. However, at the
361 blastocyst stage, the expression of HAND1 remain unchanged (Table S4, S5), coinciding with
362 the termination of METTL7A overexpression in this stage.

363

364 **Exogenous METTL7A reduces mitochondrial stress and decreases superoxide level of** 365 **bovine pre-implantation embryos**

366

367 Given mitochondria stress is precisely regulated in embryos and is associated with embryo
368 competence, and that the mitochondria related pathways are among the top regulated among
369 METTL7A^{OE} embryos at 2-, 8-cell and blastocyst stage, we next sought to determine the effect
370 of exogenous METTL7A on embryonic cell mitochondrial stress. We introduced a 6x His Tag
371 before the stop codon of METTL7A due to the lack of a suitable bovine METTL7A antibody
372 (Figure S2C, Table S1) and established a lineage tracking system by 2-cell embryo
373 microinjection. The intracellular localization of the expressed METTL7A-6xHis fusion protein
374 was evaluated 12 hours after injecting the in vitro transcribed mRNAs into one of the

375 blastomeres at the 2-cell stage (Figure 3A). We confirmed that METTL7A was uniformly
376 distributed into the cytoplasm, with no enrichment in particular organelles (Figure 3B). We found
377 that METTL7A-positive blastomeres progressed through one or two cell cycles within 12 hours,
378 whereas METTL7A-negative blastomeres were arrested with condensed nuclei and degraded
379 cytoskeleton (Figure 3B), indicating an apoptotic cell fate [41]. Moreover, METTL7A-negative
380 blastomeres exhibited activation and nuclear translocation of HIF-1 α (Figure 3B), a maker of
381 mitochondrial adaptation to oxidative stress [42]. These results suggested that METTL7A can
382 protect IVF embryos from mitochondrial stress, which was further supported by the presence of
383 attenuated mitochondrial respiratory chain activities in METTL7A^{OE} embryos (10
384 blastocysts/replicate, $p = 0.0142$) (Figure 3C-E), and was consistent with down-regulation of
385 mitochondrial pathways in METTL7A^{OE} embryos (Figure 2G-I).

386
387 To further delineate the mitochondrial stress relief conferred by METTL7A, we measured a
388 cause of oxidative stress, reactive oxygen species (ROS), in METTL7A^{OE} and control embryos.
389 As expected, superoxide levels were reduced in METTL7A^{OE} embryos compared to control (8-
390 cell stage, $p = 0.0454$; blastocyst stage, $p = 0.0182$), as measured by the MitoSox green assay
391 (Figure 3F-H). In concordance with lower superoxide levels, the levels of the intracellular
392 antioxidant glutathione in its reduced form (GSH) also decreased dramatically (8-cell stage, $p =$
393 0.0023 ; blastocyst stage, $p = 0.0007$) in METTL7A^{OE} embryos compared to control (Figure 3I, J),
394 indicating active reduction reactions in METTL7A^{OE} embryos.

395
396 Together, these results indicated that METTL7A alleviates mitochondrial stress and oxidative
397 stress during bovine pre-implantation embryo development.

398
399

400 **Exogenous METTL7A attenuates DNA damage and promotes cell cycle progression**

401
402 ROS are also genotoxic [43], prompting us to evaluate the effect of overexpression of METTL7A
403 on embryonic cell DNA damage. DNA damage occurred in normal IVP embryos (Figure 4A),
404 consistent with previous findings [44]. Using the same blastomere injection approach, we found
405 METTL7A-negative blastomeres had a higher level of DNA damage particularly at 4-cell stage,
406 as measured by γ H2A.X staining (Figure 4A). At the blastocyst stage, coincided with higher
407 blastocyst rate, a lower level of DNA damage was observed in METTL7A^{OE} embryos compared
408 to control ($p = 0.0288$) (Figure 4B, C). These results demonstrated that METTL7A reduces

409 embryonic cell oxidative stress and DNA damage, thereby promoting the developmental
410 potential of bovine IVP embryos.

411
412 Given that DNA damage can lead to the delayed cell cycles and impaired embryo development
413 [44], we further analyzed p-Chk1, an essential marker for the DNA damage checkpoint and
414 control of mitotic entry [45], in the METTL7A modulated embryos. We found that p-Chk1 is
415 significantly up-regulated in blastomeres 12 hours post-injection of METTL7A_6xHis Tag
416 (Figure 4D). However, at the blastocyst stage, the percentage of proliferating cells did not differ
417 between METTL7A^{OE} and control embryos (Figure 4E, F), consistent with our previous
418 observation that a lack of exogenous METTL7A persists into blastocyst stage embryos (Figure
419 2E, F).

420
421 In summary, our results demonstrated that METTL7A ameliorates DNA damage by reducing
422 ROS levels and enhancing DNA damage repair through p-Chk1, which promotes the 'error-free'
423 cell cycle progression and pre-implantation embryo development.

424
425
426

427 **Discussion**

428
429 In vitro fertilization (IVF) is one of the most used assisted reproductive technologies in both
430 humans and domestic species. While IVF procedures are considered safe, the in vitro
431 developing embryos are exposed to conditions during culture not normally experienced in vivo,
432 when zygote undergoes extensive epigenetic and metabolic reprogramming, potentially leading
433 to alterations in the embryonic gene expression that may result in adverse outcomes. It has long
434 been established that embryo in vitro culture induces persistent oxidative stress to embryos [46].
435 Therefore, there is a critical need to identify the strategy to protect in vitro developing embryos
436 from oxidative stress. Here, we identified a molecule, METTL7A, improves bovine embryo
437 competence by attenuating oxidative stress. Specifically, we found that exogenous METTL7A
438 promotes the developmental potential of bovine pre-implantation embryos by facilitating
439 trophectoderm lineage development and alleviating embryonic cell oxidative stress, and that the
440 resultant embryos produce normal pregnancy through conceptus elongation following embryo
441 transfer to recipients. Our findings could have broader implications for the development of
442 METTL7A molecule for optimal IVF culture conditions.

443
444 RNA-seq comparative analysis of METTL7A^{OE} and control embryos provided interesting
445 observations. For example, among the most regulated genes in 2-cell embryos, BTG2 has been
446 reported to destabilize mRNA [47], while ZSCAN5B is associated to embryonic genome
447 activation through modulating mitotic progression and safeguarding DNA damage response [48-
448 50]. Given the importance of maternal mRNA clearance for embryonic development [51],
449 METTL7A overexpression may facilitate embryonic genome activation via downstream effectors
450 like BTG2 and ZSCAN5B. Additionally, STC1 is hypoxia-responsive and promotes lipid
451 metabolism [52, 53] and its abundance is positively associated with all Ovum Pick Up-In vitro
452 Production (OPU-IVP) scores [54]. Similarly, PLA2G7 (also known as LDL-PLA2) regulates
453 phospholipid catabolism during inflammation and oxidative stress responses [55, 56]. The up-
454 regulation of STC1 and PLA2G7 in METTL7A^{OE} embryos suggested that METTL7A can
455 alleviate oxidative stress in early bovine embryos.

456
457 Mechanistically, our results have demonstrated that this is through regulation of mitochondrial
458 stress and enhancing the utilization of GSH during early embryonic cleavage stages.
459 Specifically, our study has shown that the superoxide level within the mitochondria was reduced
460 by exogenous METTL7A, indicating an ameliorated mitochondria stress in cleavage embryos,
461 which was further supported by observations of overall lower mitochondrial activities and down-
462 regulation of HIF-1 α . Surprisingly, overexpression of METTL7A decreased intracellular GSH
463 level, challenging our speculation that the S^{AMe}-dependent enzymatic activity of METTL7A
464 would contribute to the synthesis of GSH. Also, the GSH assay used in this study was only able
465 to capture intracellular GSH, while the oxidized GSSH diffused out of the cell [57]. Consequently,
466 DNA damage levels were ameliorated, with enhanced cell cycle checkpoint mechanism,
467 therefore ensuring proper cell cycle progression and development into later embryonic stages.
468 METTL7A has previously been observed to localize to the endoplasmic reticulum and the inner
469 nuclear membrane [24, 25], and thus the biological function of this protein in early embryonic
470 development has not previously been uncovered. Previous work has suggested that METTL7A
471 has methyltransferase activities toward lncRNA and thiol group substrates and could promote
472 stem cell reprogramming [27], and modulate metabolic stress to improve cell survival [28]. Here
473 we demonstrated another function of METTL7A that could shift the paradigm of energy
474 expenditure and ameliorates oxidative stress from mitochondrial metabolism, therefore
475 promoting bovine blastocyst formation in vitro. Our work nevertheless has identified a
476 completely novel, reducing oxidative stress function of this relatively understudied protein.

477 Future biochemical, genomic and structural work will investigate the direct target molecule
478 network of METTL7A in early embryos.

479
480 We have also identified a novel function of exogenous METTL7A in promoting trophectoderm
481 development and modulating the embryonic cell transcriptome associated with mitochondria
482 stress and function for improving embryo survival. Although the direct target molecule network
483 of METTL7A remains unexplored, our findings have shown that several essential transcriptional
484 factors (e.g., HAND1) were precisely modulated in the presence of METTL7A. Meanwhile, the
485 IFN-tau secretion by trophoblast remained unaffected, suggesting normal trophoblast
486 development. Moreover, we couldn't rule out if the increased trophectoderm cell number by
487 METTL7A overexpression is due to the accelerated timing of blastocyst formation, and if and
488 how reducing oxidative stress promote the progression and timing of blastulation. Future studies
489 to monitor the embryo development in real time with a time-lapse incubator could be of
490 particularly interesting.

491
492 Under in vivo conditions, the oviduct and uterus provide abundant antioxidants to tightly control
493 ROS level, creating an optimal environment for embryo growth [58]. However, current culture
494 systems fail to provide a constant antioxidant supply, leading to impaired embryo development
495 [12]. Indeed, by comparing the single blastomere transcriptomic profiles of bovine in vivo and in
496 vitro derived blastocyst, a recent study has shown that there are highly active metabolic and
497 biosynthetic processes, reduced cellular signaling, and reduced transmembrane transport
498 activities in IVP embryos that may lead to reduced developmental potential [59]. Similarly,
499 compared to IVP embryos, the up-regulated genes in vivo embryos involve in regulation of
500 embryonic development and tissue development [59] as we observed in METTL7A^{OE} embryo
501 transcriptomic datasets. Since our work was all conducted in in vitro conditions, we cannot rule
502 out the possibility that endogenous METTL7A presents in in vivo embryos, thus helps to
503 eliminate any negative oxidative stress to enhance embryo survival. Therefore, future work
504 should carefully access the expression dynamics of METTL7A in in vivo conditions.
505 Additionally, comprehensive examination of the act of METTL7A in embryos throughout
506 pregnancy and their offspring will pave the utility of METTL7A as a promising pharmaceutical
507 target for IVP embryo viability.

508
509 In summary, we have identified a novel mitochondria stress eliminating mechanism regulated by
510 METTL7A that occurs during the acquisition of oxidative stress in embryo in vitro culture. We

511 believe that this work is novel at both the mechanistic and translational levels: METTL7A not
512 only displays a unique oxidative stress relief function, but it also lays the groundwork for the
513 development of strategies that could specifically prevent oxidative stress in IVF. Future work will
514 further investigate the possibility of efficiently deliver METTL7A into IVF embryos and
515 understand its downstream molecular network targets.

516

517

518

519 **Competing interests**

520 The findings of this study were included in a U.S provisional patent application 63/698,174.

521

522 **Author contributions**

523 Conceptualization: Z.J; Methodology: L.Z, H.M, G.S; Validation: L.Z, Z.J; Formal analysis: L.Z;

524 Investigation: L.Z, H.M, G.S; Resources: Z.J; Data curation: Z.J; Writing – original draft: L.Z, Z.J;

525 Writing – review & editing: Z.J; Supervision: Z.J, A.X; Project administration: Z.J; Funding

526 acquisition: Z.J.

527

528 **Funding**

529 This work was supported by the NIH Eunice Kennedy Shriver National Institute of Child Health

530 and Human Development (R01HD102533) and USDA National Institute of Food and Agriculture

531 (2019-67016-29863).

532

533 **Data availability**

534 The raw FASTQ files and normalized read accounts per gene are available at Gene Expression

535 Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo/>) under the accession number GSE272473.

536

537 **References**

- 538 1. **2021 Assisted Reproduction Technology (ART) Fertility Clinic and National**
539 **Summary Report** [<https://www.cdc.gov/art/reports/2021/summary.html>]
- 540 2. Viana JHM: **2022 Statistics of embryo production and transfer in domestic farm**
541 **animals: the main trends for the world embryo industry still stand.** In: *Embryo*
542 *Technology Newsletter*. vol. 41. International Embryo Technologies Society; 2023: 20-38.
- 543 3. Gardner DK, Kelley RL: **Impact of the IVF laboratory environment on human**
544 **preimplantation embryo phenotype.** *J Dev Orig Health Dis* 2017, **8**(4):418-435.
- 545 4. Hansen PJ: **Implications of Assisted Reproductive Technologies for Pregnancy**
546 **Outcomes in Mammals.** *Annu Rev Anim Biosci* 2020, **8**:395-413.
- 547 5. Lin J, Wang L: **Oxidative Stress in Oocytes and Embryo Development: Implications**
548 **for In Vitro Systems.** *Antioxid Redox Signal* 2020.
- 549 6. Soto-Heras S, Paramio MT: **Impact of oxidative stress on oocyte competence for in**
550 **vitro embryo production programs.** *Res Vet Sci* 2020, **132**:342-350.
- 551 7. Correa GA, Rumpf R, Mundim TC, Franco MM, Dode MA: **Oxygen tension during in**
552 **vitro culture of bovine embryos: effect in production and expression of genes related**
553 **to oxidative stress.** *Anim Reprod Sci* 2008, **104**(2-4):132-142.
- 554 8. Fischer B, Bavister BD: **Oxygen tension in the oviduct and uterus of rhesus monkeys,**
555 **hamsters and rabbits.** *J Reprod Fertil* 1993, **99**(2):673-679.
- 556 9. Sciorio R, Smith GD: **Embryo culture at a reduced oxygen concentration of 5%: a**
557 **mini review.** *Zygote* 2019, **27**(6):355-361.
- 558 10. Nolfi-Donagan D, Braganza A, Shiva S: **Mitochondrial electron transport chain:**
559 **Oxidative phosphorylation, oxidant production, and methods of measurement.**
560 *Redox Biol* 2020, **37**:101674.
- 561 11. Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV,
562 Krasnov GS, Dmitriev AA: **ROS Generation and Antioxidant Defense Systems in**
563 **Normal and Malignant Cells.** *Oxid Med Cell Longev* 2019, **2019**:6175804.
- 564 12. Takahashi M: **Oxidative stress and redox regulation on in vitro development of**
565 **mammalian embryos.** *J Reprod Dev* 2012, **58**(1):1-9.
- 566 13. Pereira DC, Dode MA, Rumpf R: **Evaluation of different culture systems on the in**
567 **vitro production of bovine embryos.** *Theriogenology* 2005, **63**(4):1131-1141.
- 568 14. Dai W, Zou X, Jia H, Peng Y, La B, Yan Z, Gao L, Qin L, Diao F, Ma X *et al*:
569 **Peroxiredoxin 4 secreted by cumulus cells ameliorates the maturation of oocytes in**
570 **vitro.** *Biochem Biophys Res Commun* 2022, **636**(Pt 1):155-161.
- 571 15. Anjos JC, Aguiar FLN, Sa NAR, Souza JF, Cibir FWS, Alves BG, Santos RR,
572 Figueiredo JR: **Anethole improves blastocysts rates together with antioxidant**
573 **capacity when added during bovine embryo culture rather than in the in vitro**
574 **maturation medium.** *Zygote* 2019, **27**(6):382-385.
- 575 16. Bagis H, Akkoc T, Taskin C, Arat S: **Comparison of different cryopreservation**
576 **techniques: higher survival and implantation rate of frozen-thawed mouse**
577 **pronuclear embryos in the presence of beta-mercaptoethanol in post-thaw culture.**
578 *Reprod Domest Anim* 2010, **45**(6):e332-337.
- 579 17. Gupta MK, Uhm SJ, Lee HT: **Effect of vitrification and beta-mercaptoethanol on**
580 **reactive oxygen species activity and in vitro development of oocytes vitrified before**
581 **or after in vitro fertilization.** *Fertil Steril* 2010, **93**(8):2602-2607.

- 582 18. Luo D, Zhang JB, Peng YX, Liu JB, Han DX, Wang Y, Zhang Z, Yuan B, Gao Y, Chen
583 CZ *et al*: **Imperatorin improves in vitro porcine embryo development by reducing**
584 **oxidative stress and autophagy**. *Theriogenology* 2020, **146**:145-151.
- 585 19. Cambra JM, Martinez CA, Rodriguez-Martinez H, Martinez EA, Cuello C, Gil MA: **N-**
586 **(2-mercaptopropionyl)-glycine enhances in vitro pig embryo production and**
587 **reduces oxidative stress**. *Sci Rep* 2020, **10**(1):18632.
- 588 20. Wang J, Jin QG, Liu RP, Wang XQ, Li YH, Kim NH, Xu YN: **Dihydromyricetin**
589 **supplementation during in vitro culture improves porcine oocyte developmental**
590 **competence by regulating oxidative stress**. *J Reprod Dev* 2023, **69**(1):10-17.
- 591 21. Anchordoquy JP, Lizarraga RM, Anchordoquy JM, Nikoloff N, Rosa DE, Fabra MC,
592 Peral-Garcia P, Furnus CC: **Effect of cysteine, glutamate and glycine supplementation**
593 **to in vitro fertilization medium during bovine early embryo development**. *Reprod*
594 *Biol* 2019, **19**(4):349-355.
- 595 22. Lu SC: **Glutathione synthesis**. *Biochim Biophys Acta* 2013, **1830**(5):3143-3153.
- 596 23. Finkelstein JD: **Methionine metabolism in mammals**. *J Nutr Biochem* 1990, **1**(5):228-
597 237.
- 598 24. Zehmer JK, Bartz R, Liu P, Anderson RG: **Identification of a novel N-terminal**
599 **hydrophobic sequence that targets proteins to lipid droplets**. *J Cell Sci* 2008,
600 **121**(11):1852-1860.
- 601 25. Zehmer JK, Bartz R, Bisel B, Liu P, Seemann J, Anderson RG: **Targeting sequences of**
602 **UBXD8 and AAM-B reveal that the ER has a direct role in the emergence and**
603 **regression of lipid droplets**. *J Cell Sci* 2009, **122**(Pt 20):3694-3702.
- 604 26. Russell DA, Chau MK, Shi Y, Levasseur IN, Maldonado BJ, Totah RA: **METTL7A**
605 **(TMT1A) and METTL7B (TMT1B) Are Responsible for Alkyl S-Thiol Methyl**
606 **Transferase Activity in Liver**. *Drug Metab Dispos* 2023, **51**(8):1024-1034.
- 607 27. Bidy BA, Kong W, Kamimoto K, Guo C, Wayne SE, Sun T, Morris SA: **Single-cell**
608 **mapping of lineage and identity in direct reprogramming**. *Nature* 2018,
609 **564**(7735):219-224.
- 610 28. Lee E, Kim JY, Kim TK, Park SY, Im GI: **Methyltransferase-like protein 7A**
611 **(METTL7A) promotes cell survival and osteogenic differentiation under metabolic**
612 **stress**. *Cell Death Discov* 2021, **7**(1):154.
- 613 29. Pinzon-Arteaga CA, Wang Y, Wei Y, Ribeiro Orsi AE, Li L, Scatolin G, Liu L, Sakurai
614 M, Ye J, Hao M *et al*: **Bovine blastocyst-like structures derived from stem cell**
615 **cultures**. *Cell Stem Cell* 2023, **30**(5):611-616 e617.
- 616 30. Wang Y, Ming H, Yu L, Li J, Zhu L, Sun HX, Pinzon-Arteaga CA, Wu J, Jiang Z:
617 **Establishment of bovine trophoblast stem cells**. *Cell Rep* 2023:112439.
- 618 31. Mietkiewska K, Kordowitzki P, Pareek CS: **Effects of Heat Stress on Bovine Oocytes**
619 **and Early Embryonic Development-An Update**. *Cells* 2022, **11**(24).
- 620 32. Zhu L, Zhou T, Iyyappan R, Ming H, Dvoran M, Wang Y, Chen Q, Roberts RM, Susor A,
621 Jiang Z: **High-resolution ribosome profiling reveals translational selectivity for**
622 **transcripts in bovine preimplantation embryo development**. *Development* 2022,
623 **149**(21).
- 624 33. Birkenkamp-Demtroder K, Hahn SA, Mansilla F, Thorsen K, Maghnooj A, Christensen
625 R, Oster B, Orntoft TF: **Keratin23 (KRT23) knockdown decreases proliferation and**
626 **affects the DNA damage response of colon cancer cells**. *PLoS One* 2013, **8**(9):e73593.

- 627 34. Vanhooren J, Derpoorter C, Depreter B, Deneweth L, Philippe J, De Moerloose B,
628 Lammens T: **TARP as antigen in cancer immunotherapy.** *Cancer Immunol*
629 *Immunother* 2021, **70**(11):3061-3068.
- 630 35. Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H *et al*:
631 **Tumor-derived CXCL5 promotes human colorectal cancer metastasis through**
632 **activation of the ERK/Elk-1/Snail and AKT/GSK3beta/beta-catenin pathways.** *Mol*
633 *Cancer* 2017, **16**(1):70.
- 634 36. Parker MD, Musa-Aziz R, Rojas JD, Choi I, Daly CM, Boron WF: **Characterization of**
635 **human SLC4A10 as an electroneutral Na/HCO₃ cotransporter (NBCn2) with Cl-**
636 **self-exchange activity.** *J Biol Chem* 2008, **283**(19):12777-12788.
- 637 37. von Muhlinen N, Akutsu M, Ravenhill BJ, Foeglein A, Bloor S, Rutherford TJ, Freund
638 SM, Komander D, Randow F: **LC3C, bound selectively by a noncanonical LIR motif**
639 **in NDP52, is required for antibacterial autophagy.** *Mol Cell* 2012, **48**(3):329-342.
- 640 38. Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, Loney C,
641 Herder V, Allan J, Jarmson I *et al*: **A prenylated dsRNA sensor protects against severe**
642 **COVID-19.** *Science* 2021, **374**(6567):eabj3624.
- 643 39. Picard M, McEwen BS, Epel ES, Sandi C: **An energetic view of stress: Focus on**
644 **mitochondria.** *Front Neuroendocrinol* 2018, **49**:72-85.
- 645 40. Scott IC, Anson-Cartwright L, Riley P, Reda D, Cross JC: **The HAND1 basic helix-**
646 **loop-helix transcription factor regulates trophoblast differentiation via multiple**
647 **mechanisms.** *Mol Cell Biol* 2000, **20**(2):530-541.
- 648 41. Elmore S: **Apoptosis: a review of programmed cell death.** *Toxicol Pathol* 2007,
649 **35**(4):495-516.
- 650 42. Bao X, Zhang J, Huang G, Yan J, Xu C, Dou Z, Sun C, Zhang H: **The crosstalk between**
651 **HIFs and mitochondrial dysfunctions in cancer development.** *Cell Death Dis* 2021,
652 **12**(2):215.
- 653 43. Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD: **ROS and the DNA**
654 **damage response in cancer.** *Redox Biol* 2019, **25**:101084.
- 655 44. Takahashi M, Keicho K, Takahashi H, Ogawa H, Schultz RM, Okano A: **Effect of**
656 **oxidative stress on development and DNA damage in in-vitro cultured bovine**
657 **embryos by comet assay.** *Theriogenology* 2000, **54**(1):137-145.
- 658 45. Rhind N, Russell P: **Chk1 and Cds1: linchpins of the DNA damage and replication**
659 **checkpoint pathways.** *J Cell Sci* 2000, **113** (Pt 22)(Pt 22):3889-3896.
- 660 46. de Lima CB, Dos Santos EC, Ispada J, Fontes PK, Nogueira MFG, Dos Santos CMD,
661 Milazzotto MP: **The dynamics between in vitro culture and metabolism: embryonic**
662 **adaptation to environmental changes.** *Sci Rep* 2020, **10**(1):15672.
- 663 47. Hwang SS, Lim J, Yu Z, Kong P, Sefik E, Xu H, Harman CCD, Kim LK, Lee GR, Li HB
664 *et al*: **mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence.**
665 *Science* 2020, **367**(6483):1255-1260.
- 666 48. Liu X, Wang Y, Gao Y, Su J, Zhang J, Xing X, Zhou C, Yao K, An Q, Zhang Y: **H3K9**
667 **demethylase KDM4E is an epigenetic regulator for bovine embryonic development**
668 **and a defective factor for nuclear reprogramming.** *Development* 2018, **145**(4).
- 669 49. Sun Y, Zhang H, Kazemian M, Troy JM, Seward C, Lu X, Stubbs L: **ZSCAN5B and**
670 **primate-specific paralogs bind RNA polymerase III genes and extra-TFIIC (ETC)**
671 **sites to modulate mitotic progression.** *Oncotarget* 2016, **7**(45):72571-72592.

- 672 50. Ogawa S, Yamada M, Nakamura A, Sugawara T, Nakamura A, Miyajima S, Harada Y,
673 Ooka R, Okawa R, Miyauchi J *et al*: **Zscan5b Deficiency Impairs DNA Damage**
674 **Response and Causes Chromosomal Aberrations during Mitosis.** *Stem Cell Reports*
675 2019, **12**(6):1366-1379.
- 676 51. Zhao LW, Zhu YZ, Wu YW, Pi SB, Shen L, Fan HY: **Nuclear poly(A) binding protein**
677 **1 (PABPN1) mediates zygotic genome activation-dependent maternal mRNA**
678 **clearance during mouse early embryonic development.** *Nucleic Acids Res* 2022,
679 **50**(1):458-472.
- 680 52. Lin F, Li X, Wang X, Sun H, Wang Z, Wang X: **Stanniocalcin 1 promotes metastasis,**
681 **lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling**
682 **axis in ovarian cancer.** *J Exp Clin Cancer Res* 2022, **41**(1):129.
- 683 53. Law AY, Ching LY, Lai KP, Wong CK: **Identification and characterization of the**
684 **hypoxia-responsive element in human stanniocalcin-1 gene.** *Mol Cell Endocrinol*
685 2010, **314**(1):118-127.
- 686 54. Mazzoni G, Salleh SM, Freude K, Pedersen HS, Stroebach L, Callesen H, Hyttel P,
687 Kadarmideen HN: **Identification of potential biomarkers in donor cows for in vitro**
688 **embryo production by granulosa cell transcriptomics.** *PLoS One* 2017,
689 **12**(4):e0175464.
- 690 55. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S,
691 Le Trong H, Cousens LS, Zimmerman GA *et al*: **Anti-inflammatory properties of a**
692 **platelet-activating factor acetylhydrolase.** *Nature* 1995, **374**(6522):549-553.
- 693 56. Spadaro O, Youm Y, Shchukina I, Ryu S, Sidorov S, Ravussin A, Nguyen K, Aladyeva E,
694 Predeus AN, Smith SR *et al*: **Caloric restriction in humans reveals immunometabolic**
695 **regulators of health span.** *Science* 2022, **375**(6581):671-677.
- 696 57. Ballatori N, Krance SM, Marchan R, Hammond CL: **Plasma membrane glutathione**
697 **transporters and their roles in cell physiology and pathophysiology.** *Mol Aspects Med*
698 2009, **30**(1-2):13-28.
- 699 58. Lapointe J, Bilodeau JF: **Antioxidant defenses are modulated in the cow oviduct**
700 **during the estrous cycle.** *Biol Reprod* 2003, **68**(4):1157-1164.
- 701 59. Ming H, Zhang M, Rajput S, Logsdon D, Zhu L, Schoolcraft WB, Krisher RL, Jiang Z,
702 Yuan Y: **In vitro culture alters cell lineage composition and cellular metabolism of**
703 **bovine blastocystdagger.** *Biol Reprod* 2024, **111**(1):11-27.
- 704
705

706 **Figure Legends**

707

708 **Figure 1. Exogenous METTL7A improves the developmental potential of bovine IVP**

709 **embryos. A.** The cleavage OF METTL7A^{OE} embryos (n = 29) compared to the vehicle control
710 (n = 18). **B.** The blastocyst rate of METTL7A^{OE} embryos (n = 11) compared to the control (n =
711 11). **C.** A representative image of bovine METTL7A^{OE} embryos, scale bar = 100 μ m. **D.**
712 Immunostaining analysis of CDX2 (trophectoderm, TE marker) and SOX2 (inner cell mass, ICM
713 marker) in METTL7A^{OE} embryos compared to the control, scale bar = 50 μ m. **E.** The total TE
714 cell number counts between METTL7A^{OE} blastocysts (n = 5) compared to the control (n = 5). **F.**
715 The total ICM cell number counts between METTL7A^{OE} blastocysts (n = 5) compared to the
716 control (n = 5). **G.** The TE/ICM cell number ratio between METTL7A^{OE} blastocysts compared to
717 the control. **H.** A representative bright field image of day 12 (E12) elongated embryos from
718 METTL7A^{OE} and control embryo transfer, scale bar = 500 μ m. **I.** The serum INF-tau levels of
719 surrogate cows with METTL7A^{OE} embryo transfer (n = 2) compared to the control (n = 2) on the
720 day of flushing. **J.** Immunostaining analysis of CDX2 (TE marker), SOX2 (embryonic disc
721 marker), and GATA6 (hypoblast marker) in E12 embryos flushed out from the METTL7A^{OE} and
722 control embryo transfer, scale bar = 50 μ m.

723

724

725 **Figure 2. The transcriptomic analysis of METTL7A^{OE} embryos at 2-, 8-cell, and ICM/TE**

726 **compared to control. A.** Heatmap of the samples from the same stages of bovine embryos
727 from the METTL7A^{OE} and control group. **B.** Principal component analysis (PCA) of the
728 transcriptomes of METTL7A^{OE} and control embryos at different developmental stages. **C-F**
729 Volcano plots showing the number of up- or down-regulated genes in METTL7A^{OE} embryos
730 compared to control at 2-cell (C), 8-cell (D), ICM (E) and TE (F) stages (FDR < 0.05, $|\log_2FC| >$
731 1). The most significant up-regulated genes in METTL7A^{OE} embryos compared to the control
732 are highlighted. **(G-I)** The top GO terms of up- and down-regulated genes METTL7A^{OE} embryos
733 compared to the control at of 8-cell (G), ICM (H) and TE (I) stages.

734

735 **Figure 3. Exogenous METTL7A reduces mitochondrial stress and decreases superoxide**

736 **level of bovine pre-implantation embryos. A.** Experimental scheme of injecting METTL7A
737 IVT-RNA into one blastomere of 2-cell embryos. **B.** Immunostaining analysis of F-actin,
738 mitochondrial stress marker (HIF1a), and METTL7A-6xHisTag in METTL7A^{OE} blastomeres and
739 control. The red arrow points to condensed chromatin and degradation of actin filament, scale

740 bar = 50µm. After 12 hours of injection, METTL7A^{OE} blastomeres developed through 1 or 2 cell
741 cycles, while non-injected blastomeres were arrested (n = 5, 4/5 or 80%) with described
742 phenotype. **C.** Experimental scheme of zygotic injection and western blot analysis. **D** and **E.**
743 Western blot analysis of Succinate Dehydrogenase Complex Flavoprotein Subunit A (SDHA, a
744 marker for mitochondrial respiratory activity) in METTL7A^{OE} (n = 6) blastocysts compared to
745 control (n = 7). **F.** The immunostaining analysis of superoxide level measured by MitoSox green
746 in METTL7A^{OE} embryos and control at 8-cell (n = 13 embryos for both groups) and blastocyst
747 (n = 10 embryos for both groups) stage, scale bar, 50µm. **G** and **H.** The quantification of
748 superoxide level in METTL7A^{OE} embryos and control at 8-cell (**G**) and blastocyst stage (**H**). **I**
749 and **J.** The GSH level METTL7A^{OE} embryos and control at 8-cell (**I**, n = 6 for both groups) and
750 blastocyst stage (**J**, n = 3 for both groups).

751
752 **Figure 4. Exogenous METTL7A attenuates DNA damage and promotes cell cycle**
753 **progression.** **A.** Immunostaining analysis of F-actin, γH2A.X (DNA damage marker) and
754 METTL7A-6xHisTag in METTL7A^{OE} blastomeres (n = 5) and control (non-injected blastomeres
755 and IVF embryos: METTL7A^{OE} negative blastomere), scale bar = 50µm. **B** and **C.** Western blot
756 analysis and quantification of γH2A.X in METTL7A^{OE} embryos (n = 3) and the vehicle control (n
757 = 4) at blastocyst stage 7 days after zygotic injection. **D.** Immunostaining analysis of p-Chk1
758 (cell cycle checkpoint marker) in METTL7A^{OE} and IVF control embryos at the cleavage stage,
759 scale bar = 50µm. **E** and **F.** Immunostaining analysis of the proliferative cells (Ki67⁺) in
760 METTL7A^{OE} blastocyst and control group. After 12 hours of zygotic injection, METTL7A^{OE}
761 blastomeres developed through 1 or 2 cell cycles, while non-injected blastomeres were arrested
762 (n = 5).

763
764
765

766 **Supplementary Information**

767 **Figure S1.** The transcriptional and translational abundances of METTL7A in bovine oocytes
768 and pre-implantation embryo development.

769

770 **Figure S2. A.** An illustrate image showing that ICM is isolated from blastocyst by blastomere
771 biopsy. **B.** The confirmation of TE and ICM isolation by immunostaining analysis of SOX2 and
772 CDX2 markers, respectively, scale bar = 50µm.

773

774 **Figure S3.** Original images of complete membrane of western blot analysis of SHDA in the
775 METTL7A^{OE} embryos. **A.** First membrane for SDHA and ACTB. **B.** Second membrane for
776 ACTB. **C.** Second membrane for SDHA. OE, METTL7A^{OE} (n = 6); KO, METTL7A knockout (n =
777 2, note: METTL7A KO experiment was excluded from revised manuscript suggested by the
778 reviewers); VC, vehicle control (n = 7); M, marker (Fisher Scientific cat# 26619). Red arrows
779 indicated SDHA (70 kDa); green arrows, ACTB (45 kDa). Blue arrow, GAPDH (37 kDa). ACTB
780 bands in **C** were due to insufficient stripping before staining SDHA, but only ACTB bands in **B**
781 were used for quantification.

782

783 Original images of complete membrane of western blot analysis of γ H2A.X. **A.** Chemi-plot and
784 overlay-plot of ACTB (45 kDa). **B.** Chemi-plot and overlay-plot of γ H2A.X (17 kDa). OE,
785 METTL7A^{OE} (n = 3); VC, vehicle control (n = 4); M, marker (Fisher Scientific cat# 26619). Due
786 to the long exposure time required, γ H2A.X bands did not show up in the overlay-plot.

787

788 **Table S1.** Oligos and antibodies used in this study.

789

790 **Table S2.** Differentially expressed genes in METTL7A^{OE} embryos compared to the control at
791 the 2-cell stage.

792

793 **Table S3.** Differentially expressed genes in METTL7A^{OE} embryos compared to the control at
794 the 8-cell stage.

795

796 **Table S4.** Differentially expressed genes in METTL7A^{OE} embryos compared to the control at
797 the ICM stage.

798

799 **Table S5.** Differentially expressed genes in METTL7A^{OE} embryos compared to the control at
800 the TE stage.









